A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge

A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model

(2019) E.M. Kennedy et al.   VACCINE

Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins

(2018) Adrián Lázaro-Frías et al.   JOURNAL OF VIROLOGY

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP

(2018) Carly M. Bliss et al.   Scientific Reports

A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge

(2018) Arban Domi et al.   Scientific Reports

Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development

(2018) Hoai J. Hallam et al.   npj Vaccines

The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts

(2018) Massinissa Si Mehand et al.   ANTIVIRAL RESEARCH

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

(2017) Chad E Mire et al.   NATURE MEDICINE

Structural basis for antibody-mediated neutralization of Lassa virus

(2017) Kathryn M. Hastie et al.   SCIENCE

HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site

(2017) Nathanael P. McCurley et al.   PLoS One

A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model

(2017) Aaron C. Brault et al.   Scientific Reports

Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies

(2016) Robert W. Cross et al.   ANTIVIRAL RESEARCH

Crystal Structure of the Oligomeric Form of Lassa Virus Matrix Protein Z

(2016) Kathryn M. Hastie et al.   JOURNAL OF VIROLOGY

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

(2016) James E. Robinson et al.   Nature Communications

DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus

(2016) Melanie Thompson et al.   PLoS One

New Hosts of The Lassa Virus

(2016) Ayodeji Olayemi et al.   Scientific Reports

Past, present, and future of arenavirus taxonomy

(2015) Sheli R. Radoshitzky et al.   ARCHIVES OF VIROLOGY

Imported Lassa fever: a report of 2 cases in Ghana

(2015) Nicholas N.A. Kyei et al.   BMC INFECTIOUS DISEASES

Cis- and cell-type-dependent trans-requirements for Lassa virus-like particle production

(2015) Shuzo Urata et al.   JOURNAL OF GENERAL VIROLOGY

Mapping the zoonotic niche of Lassa fever in Africa

(2015) Adrian Q. N. Mylne et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

A DNA Vaccine against Yellow Fever Virus: Development and Evaluation

(2015) Milton Maciel et al.   PLoS Neglected Tropical Diseases

A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses

(2015) David Safronetz et al.   PLoS Neglected Tropical Diseases

Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection

(2015) Rami Sommerstein et al.   PLoS Pathogens

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

(2015) E. T. Overton et al.   Open Forum Infectious Diseases

Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

(2014) Paul A. Goepfert et al.   JOURNAL OF INFECTIOUS DISEASES

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases

(2014) Arwen Altenburg et al.   Viruses-Basel

HIV epidemic among key populations in west Africa

(2014) Gaston Djomand et al.   Current Opinion in HIV and AIDS

An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity

(2013) Juan C Zapata et al.   Virology Journal

Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials

(2013) Stephan Ölschläger et al.   PLoS Pathogens

Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination

(2012) Céline Verheust et al.   VACCINE

Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model

(2012) Marco A. Goicochea et al.   VACCINE

Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine

(2012) Michael Hellerstein et al.   Human Vaccines & Immunotherapeutics

Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles

(2011) Paul A. Goepfert et al.   JOURNAL OF INFECTIOUS DISEASES

Elucidating and Minimizing the Loss by Recombinant Vaccinia Virus of Human Immunodeficiency Virus Gene Expression Resulting from Spontaneous Mutations and Positive Selection

(2009) L. S. Wyatt et al.   JOURNAL OF VIROLOGY

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines

(2009) Patricia L. Earl et al.   VACCINE

Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates

(2008) Igor S. Lukashevich et al.   VACCINE

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines

(2007) Linda S. Wyatt et al.   VACCINE